RxDoctor Payments Data

Jose Martinez, MD

Internal Medicine · Wake Forest, NCNPI 1417907858

Payments from drug & device makers

$503in general payments, 2019–2025

Across 17 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$199
  • Johnson & Johnson$110
  • Inari Medical, Inc.$65
  • Otsuka America Pharmaceutical, Inc.$36
  • Novartis$25
  • UCB, Inc.$22
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$169,147
Medicare patients
185
Services billed
1,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$73,654
TriumeqAbacavir/Dolutegravir/Lamivudi12$47,973
XtandiEnzalutamide24$42,729
TrulicityDulaglutide37$37,675
TradjentaLinagliptin115$29,988
SantylCollagenase Clostridium Hist.19$14,758
JardianceEmpagliflozin44$14,036
XareltoRivaroxaban46$13,084
Atorvastatin Calcium496$9,250
EntrestoSacubitril/Valsartan29$8,990
Incruse ElliptaUmeclidinium Bromide18$6,713
AbrysvoRsv Vacc, Pref A And Pref B/Pf21$6,636
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog79$6,410
Gabapentin255$5,761
RestasisCyclosporine14$5,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$22$37,67537 claims
Johnson & JohnsonXarelto$110$13,08446 claims
NovartisEntresto$25$8,99029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wake Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →